Platinum-based chemotherapy doublet or pembrolizumab monotherapy for patients with a high level of tumor PD-L1 expression (≥1%) were the standard first-line therapy for advanced NSCLC without treatable driver mutations (7–10). The gene discussed is CD274; the disease is neoplasm.